Comparative Biodistribution and Radiation Dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in Patients with Neuroendocrine Tumors
Comparative Biodistribution and Radiation Dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in Patients with Neuroendocrine Tumors
复制标题
DOI：
10.2967/jnumed.113.120600
复制
发表时间：
2013-10-01
影响因子：
9.3
通讯作者：
Lubberink, Mark
中科院分区：
文献类型：
--
作者：
Sandstrom, Mattias;Velikyan, Irina;Lubberink, Mark
GA-68-DOTATOC和GA-68-DOTATE是两种放射性标记的生长抑素类似物，用于PET活体诊断神经内分泌肿瘤。本工作的目的是测量它们的相对生物分布和辐射剂量学。方法：选择10例神经内分泌肿瘤患者。每例患者在注射示踪剂后1、2、3h连续3天进行45min动态扫描和3次全身PET/CT扫描。吸收剂量用Olinda/exm 1.1计算。结果：9例患者的资料均可纳入分析。在主要器官中，在注射后1、2和3h，脾的摄取最高，其次是肾脏和肝脏。对于这两种示踪剂，器官吸收剂量最高的是脾和膀胱壁，其次是肾脏、肾上腺和肝脏。Ga-68-DOTATE在肝脏和胆囊壁的吸收剂量略高，但显著高于后者。两种示踪剂的总有效剂量分别为0.021±0.003 mSv/mBq。结论：Ga-68-DOTATE和Ga-68-DOTATOC典型的100-MBq剂量对两种示踪剂的有效剂量均为2.1 mSv。因此，从辐射剂量学的角度来看，对于生长抑素受体表达的肿瘤的PET/CT评估，这两种示踪剂都不是首选。
Ga-68-DOTATOC and Ga-68-DOTATATE are 2 radiolabeled somatostatin analogs for in vivo diagnosis of neuroendocrine tumors with PET. The aim of the present work was to measure their comparative biodistribution and radiation dosimetry. Methods: Ten patients diagnosed with neuroendocrine tumors were included. Each patient underwent a 45-min dynamic and 3 whole-body PET/CT scans at 1, 2, and 3 h after injection of each tracer on consecutive days. Absorbed doses were calculated using OLINDA/EXM 1.1. Results: Data from 9 patients could be included in the analysis. Of the major organs, the highest uptake at 1, 2, and 3 h after injection was observed in the spleen, followed by kidneys and liver. For both tracers, the highest absorbed organ doses were seen in the spleen and urinary bladder wall, followed by kidney, adrenals, and liver. The absorbed doses to the liver and gallbladder wall were slightly but significantly higher for Ga-68-DOTATATE. The total effective dose was 0.021 +/- 0.003 mSv/MBq for both tracers. Conclusion: The effective dose for a typical 100-MBq administration of Ga-68-DOTATATE and Ga-68-DOTATOC is 2.1 mSv for both tracers. Therefore, from a radiation dosimetry point of view, there is no preference for either tracer for PET/CT evaluation of somatostatin receptor-expressing tumors.